JP7669325B2 - 化合物及びフマル酸の結晶形態、医薬組成物及びコロナウイルス誘発性疾患の治療方法 - Google Patents

化合物及びフマル酸の結晶形態、医薬組成物及びコロナウイルス誘発性疾患の治療方法 Download PDF

Info

Publication number
JP7669325B2
JP7669325B2 JP2022172288A JP2022172288A JP7669325B2 JP 7669325 B2 JP7669325 B2 JP 7669325B2 JP 2022172288 A JP2022172288 A JP 2022172288A JP 2022172288 A JP2022172288 A JP 2022172288A JP 7669325 B2 JP7669325 B2 JP 7669325B2
Authority
JP
Japan
Prior art keywords
present
pharmaceutical composition
fumaric acid
tablet
crystalline form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022172288A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023166957A (ja
Inventor
魏偉業
楊建楠
呉小涛
趙涛涛
王浩
李超
曲蕾
王斌
Original Assignee
北京遠大九和薬業有限公司
南京済群医薬科技股▲ふん▼有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=86385250&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7669325(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from CN202210500296.8A external-priority patent/CN114591304B/zh
Priority claimed from CN202210644417.6A external-priority patent/CN114716417B/zh
Priority claimed from CN202211119888.1A external-priority patent/CN115252619B/zh
Application filed by 北京遠大九和薬業有限公司, 南京済群医薬科技股▲ふん▼有限公司 filed Critical 北京遠大九和薬業有限公司
Publication of JP2023166957A publication Critical patent/JP2023166957A/ja
Priority to JP2023216987A priority Critical patent/JP2024045113A/ja
Priority to JP2023216988A priority patent/JP2024056678A/ja
Application granted granted Critical
Publication of JP7669325B2 publication Critical patent/JP7669325B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
JP2022172288A 2022-05-10 2022-10-27 化合物及びフマル酸の結晶形態、医薬組成物及びコロナウイルス誘発性疾患の治療方法 Active JP7669325B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023216987A JP2024045113A (ja) 2022-05-10 2023-12-22 化合物及びフマル酸の結晶形態、医薬組成物及びコロナウイルス誘発性疾患の治療方法
JP2023216988A JP2024056678A (ja) 2022-05-10 2023-12-22 化合物及びフマル酸の結晶形態、医薬組成物及びコロナウイルス誘発性疾患の治療方法

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
CN202210500296.8 2022-05-10
CN202210500296.8A CN114591304B (zh) 2022-05-10 2022-05-10 一种化合物的结晶形式及其制备方法和用途
CN202210644417.6 2022-06-09
CN202210644417.6A CN114716417B (zh) 2022-06-09 2022-06-09 化合物与富马酸的结晶形式的原料药及其药物组合物和用途
CN202211119888.1A CN115252619B (zh) 2022-05-27 2022-09-15 药物组合物及其制备方法和用于治疗冠状病毒引起的疾病的用途
CN202211119888.1 2022-09-15

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2023216988A Division JP2024056678A (ja) 2022-05-10 2023-12-22 化合物及びフマル酸の結晶形態、医薬組成物及びコロナウイルス誘発性疾患の治療方法
JP2023216987A Division JP2024045113A (ja) 2022-05-10 2023-12-22 化合物及びフマル酸の結晶形態、医薬組成物及びコロナウイルス誘発性疾患の治療方法

Publications (2)

Publication Number Publication Date
JP2023166957A JP2023166957A (ja) 2023-11-22
JP7669325B2 true JP7669325B2 (ja) 2025-04-28

Family

ID=86385250

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2022172288A Active JP7669325B2 (ja) 2022-05-10 2022-10-27 化合物及びフマル酸の結晶形態、医薬組成物及びコロナウイルス誘発性疾患の治療方法
JP2023216988A Pending JP2024056678A (ja) 2022-05-10 2023-12-22 化合物及びフマル酸の結晶形態、医薬組成物及びコロナウイルス誘発性疾患の治療方法
JP2023216987A Pending JP2024045113A (ja) 2022-05-10 2023-12-22 化合物及びフマル酸の結晶形態、医薬組成物及びコロナウイルス誘発性疾患の治療方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023216988A Pending JP2024056678A (ja) 2022-05-10 2023-12-22 化合物及びフマル酸の結晶形態、医薬組成物及びコロナウイルス誘発性疾患の治療方法
JP2023216987A Pending JP2024045113A (ja) 2022-05-10 2023-12-22 化合物及びフマル酸の結晶形態、医薬組成物及びコロナウイルス誘発性疾患の治療方法

Country Status (3)

Country Link
US (1) US11655240B1 (enExample)
JP (3) JP7669325B2 (enExample)
KR (1) KR102533637B1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230302005A1 (en) * 2022-03-25 2023-09-28 Beijing Grand Johamu Pharmaceutical Company, Ltd. Active pharmaceutical ingredient, preparation method thereof, and pharmaceutical composition including the same
US20230365536A1 (en) * 2022-05-10 2023-11-16 Beijing Grand Johamu Pharmaceutical Company, Ltd. Crystal form of compound and fumaric acid, pharmaceutical composition and method for treating coronavirus-induced diseases

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008143239A1 (ja) 2007-05-21 2008-11-27 Toray Industries, Inc. 結晶性微粉化粒子
JP2014520778A (ja) 2011-07-08 2014-08-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 医薬組成物、治療のための方法およびその使用
JP2017206454A (ja) 2016-05-17 2017-11-24 エルメッド エーザイ株式会社 レベチラセタム含有医薬組成物及びその製造方法
CN114591304A (zh) 2022-05-10 2022-06-07 北京远大九和药业有限公司 一种化合物的结晶形式及其制备方法和用途
WO2022138988A1 (ja) 2021-04-14 2022-06-30 塩野義製薬株式会社 ウイルス増殖阻害作用を有するトリアジン誘導体およびそれらを含有する医薬組成物
CN114716417A (zh) 2022-06-09 2022-07-08 北京远大九和药业有限公司 化合物与富马酸的结晶形式的原料药及其药物组合物和用途
CN114948969A (zh) 2022-05-27 2022-08-30 北京远大九和药业有限公司 包含化合物与富马酸的结晶形式的药物组合物及其制备方法和用途
CN115252619A (zh) 2022-05-27 2022-11-01 北京远大九和药业有限公司 药物组合物及其制备方法和用于治疗冠状病毒引起的疾病的用途
WO2023027198A1 (ja) 2021-11-24 2023-03-02 塩野義製薬株式会社 トリアジン誘導体を含有する経口投与する製剤

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101214242A (zh) 2007-01-05 2008-07-09 上海艾力斯医药科技有限公司 新的药用组合物
CN101584696A (zh) 2008-05-21 2009-11-25 上海艾力斯医药科技有限公司 包含喹唑啉衍生物的组合物及制备方法、用途
CN101596189A (zh) 2008-06-05 2009-12-09 上海艾力斯生物医药有限公司 含有咪唑-5-羧酸类衍生物的药用组合物
BR112013002984B1 (pt) * 2010-08-10 2021-10-26 Shionogi & Co., Ltd Compostos derivados de triazina e composições farmacêuticas que os compreendem
EP2468762A1 (en) * 2010-11-30 2012-06-27 Dr. Falk Pharma Gmbh Optimized synthesis of pure, non-polymorphic, crystalline bile acids with defined particle size
CN106994121B (zh) 2016-01-26 2021-07-02 江苏恒瑞医药股份有限公司 一种用于治疗癌症的药物组合物
WO2021183774A1 (en) 2020-03-12 2021-09-16 Angion Biomedica Corp. Treating acute respiratory distress
CN113521289A (zh) 2020-04-16 2021-10-22 中国科学院上海药物研究所 15种药物有效成分在抗病毒感染中的应用
WO2021226561A1 (en) 2020-05-07 2021-11-11 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Covid-19 therapeutics and methods of treatment
AU2021289665A1 (en) 2020-06-10 2022-12-15 Aligos Therapeutics, Inc. Anti-viral compounds for treating coronavirus, picornavirus, and norovirus infections
KR20210153908A (ko) * 2020-06-11 2021-12-20 제이더블유중외제약 주식회사 코로나바이러스감염증-19(covid-19) 치료용 조성물
KR20210158795A (ko) * 2020-06-24 2021-12-31 뉴지랩파마 주식회사 나파모스타트 메실레이트를 유효성분으로 포함하는 경구용 약제학적 조성물
WO2022035911A2 (en) 2020-08-11 2022-02-17 Tutela Pharmaceuticals, Inc. Methods of treating coronavirus infections by co-administering an fkbp ligand and an antiviral agent
WO2022053993A2 (en) 2020-09-12 2022-03-17 Mylan Laboratories Limited Treatments for sars-cov-2 infection (covid-19)
CN113198019A (zh) 2021-05-06 2021-08-03 叶绍朋 用于新冠状病毒肺炎感染初期治疗的药物组方

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008143239A1 (ja) 2007-05-21 2008-11-27 Toray Industries, Inc. 結晶性微粉化粒子
JP2014520778A (ja) 2011-07-08 2014-08-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 医薬組成物、治療のための方法およびその使用
JP2017206454A (ja) 2016-05-17 2017-11-24 エルメッド エーザイ株式会社 レベチラセタム含有医薬組成物及びその製造方法
WO2022138988A1 (ja) 2021-04-14 2022-06-30 塩野義製薬株式会社 ウイルス増殖阻害作用を有するトリアジン誘導体およびそれらを含有する医薬組成物
WO2023027198A1 (ja) 2021-11-24 2023-03-02 塩野義製薬株式会社 トリアジン誘導体を含有する経口投与する製剤
CN114591304A (zh) 2022-05-10 2022-06-07 北京远大九和药业有限公司 一种化合物的结晶形式及其制备方法和用途
CN114948969A (zh) 2022-05-27 2022-08-30 北京远大九和药业有限公司 包含化合物与富马酸的结晶形式的药物组合物及其制备方法和用途
CN115252619A (zh) 2022-05-27 2022-11-01 北京远大九和药业有限公司 药物组合物及其制备方法和用于治疗冠状病毒引起的疾病的用途
CN114716417A (zh) 2022-06-09 2022-07-08 北京远大九和药业有限公司 化合物与富马酸的结晶形式的原料药及其药物组合物和用途

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Advanced Powder Technology, 31,(2020),1280-1289
Journal of Medical Chemistry, 2022.03.30,65,6499-6512
Particle Size Analysis of Active Pharmaceutical Ingredients (APIs)

Also Published As

Publication number Publication date
JP2023166957A (ja) 2023-11-22
JP2024045113A (ja) 2024-04-02
US11655240B1 (en) 2023-05-23
JP2024056678A (ja) 2024-04-23
KR102533637B1 (ko) 2023-05-16

Similar Documents

Publication Publication Date Title
JP2024056678A (ja) 化合物及びフマル酸の結晶形態、医薬組成物及びコロナウイルス誘発性疾患の治療方法
EP2167046B1 (en) Pharmaceutical solid preparation comprising benzazepines and production method thereof
CN115969858B (zh) 药物组合物及其制备方法和用于治疗冠状病毒引起的疾病的用途
US20230285386A1 (en) IMMEDIATE RELEASE FORMULATIONS OF d-LYSERGIC ACID DIETHYLAMIDE FOR THERAPEUTIC APPLICATIONS
CN114716417B (zh) 化合物与富马酸的结晶形式的原料药及其药物组合物和用途
US20230365536A1 (en) Crystal form of compound and fumaric acid, pharmaceutical composition and method for treating coronavirus-induced diseases
US20230302005A1 (en) Active pharmaceutical ingredient, preparation method thereof, and pharmaceutical composition including the same
JP2006206612A (ja) 固形製剤用組成物
JP5103173B2 (ja) ジヒドロピリジン系化合物の分解を防止する方法
JPWO2009123169A1 (ja) アミド誘導体含有医薬組成物
CN118178409A (zh) 一种艾沙康唑药物组合物及其制备方法
EP3731817B1 (en) Pharmaceutical composition of lenalidomide pharmaceutically acceptable acid addition salt
CN114948969B (zh) 包含化合物与富马酸的结晶形式的药物组合物及其制备方法和用途
JPWO2020111089A1 (ja) 医薬組成物
CN114053421A (zh) 一种血小板生成素受体激动剂的组合物及其制备方法
EP4081193A1 (en) Composition for the preparation of perindopril arginine granules, a method for their preparation and pharmaceutical composition comprising the granules
JP4742679B2 (ja) 固形製剤用組成物
WO2007060802A1 (ja) 固形製剤および製剤組成物
JP3934150B1 (ja) 固形製剤および製剤組成物
JP7480983B2 (ja) レベチラセタム含有製剤
WO2013157584A1 (ja) カプセル剤
JP2015193611A (ja) 安定な固形医薬組成物
WO2024164066A1 (en) Crystalline forms of acalabrutinib maleate
JPWO2007049626A1 (ja) カベルゴリン含有経口固形製剤
WO2017188362A1 (ja) トスフロキサシントシル酸塩、崩壊剤および酸性アミノ酸を含む錠剤

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230120

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20230120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230328

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230628

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230912

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20231129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250218

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250416

R150 Certificate of patent or registration of utility model

Ref document number: 7669325

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150